Cediranib maleate is under clinical development by AstraZeneca and currently in Phase III for Epithelial Ovarian Cancer. According to GlobalData, Phase III drugs for Epithelial Ovarian Cancer have a 35% phase transition success rate (PTSR) indication benchmark for progressing into Pre-Registration. GlobalData’s report assesses how Cediranib maleate’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Cediranib maleate overview
Cediranib (AZD2171, Recentin) is under development for the treatment of cervical cancer, platinum-sensitive relapsed epithelial ovarian cancer, including fallopian tube and/or primary peritoneal cancer. The drug candidate is administered orally as a coated tablet. It targets all three vascular endothelial growth factor receptor (VEGFR-1,-2,-3) tyrosine kinases.
It was also under development for the treatment of endometrial cancer, colorectal cancer, glioblastoma multiforme (GBM), gastrointestinal stromal tumors (GIST), renal cell carcinoma, solid tumors, non-small cell lung cancer, liver diseases, acute myelocytic leukemia (AML), head and neck cancer, alveolar soft part sarcoma, thyroid cancer and prostate cancer, breast cancer, malignant pleural mesothelioma.
AstraZeneca is a biopharmaceutical company, which is focused on discovery, production and commercialization of a range of prescription drugs. It develops products related to therapy areas such as respiratory, cardiovascular, renal and metabolic diseases, cancer, autoimmune, infection and neurological diseases. The company’s product portfolio includes biologics, prescription pharmaceuticals and vaccines. AstraZeneca sells its products through wholly-owned local marketing companies, distributors and local representative offices. The company markets its products to primary care and specialty care physicians. The COVID-19 Vaccine AstraZeneca has been approved for conditional marketing or emergency use. The company operates in Europe, the Americas, Asia, Africa and Australasia. AstraZeneca is headquartered in Cambridge, Cambridgeshire, the UK.
For a complete picture of Cediranib maleate’s drug-specific PTSR and LoA scores, buy the report here.